News

Stivarga approved for Metastatic Colorectal Cancer
Colorectal cancer remains the second leading cause of cancer-related death in the United States. Metastatic colorectal cancer refers to cancer that has spread from the colon to distant sites in the... Leggi tutto
Novartis drug Ilaris® approved by FDA
Basel, May 10, 2013 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (... Leggi tutto
Stelara (ustekinumab)
Stelara is a solution for injection that contains the active substance ustekinumab. It is available in a vial or in a prefilled syringe. Each vial or syringe contains either 45 or 90 mg ustekinumab.... Leggi tutto
Iluvien (sustained release fluocinolone acetonide)
ILUVIEN is an injectable, non-erodible, intravitreal implant for the treatment of DME, a potentially blinding condition that affects approximately one million people in the U.S. alone. ILUVIEN is... Leggi tutto
Kadcyla (trastuzumab emtansine)
New personalised medicine helped people in Phase III study live longer, compared to standard treatment Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (... Leggi tutto
Jakavi
Jakavi® (ruxolitinib) is an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases and was approved by the European Commission in August 2012 for the treatment of disease-related splenomegaly or... Leggi tutto
CAPRELSA® (vandetanib)
Tuesday, 21 February 2012 AstraZeneca today announced that the European Commission has granted marketing authorisation for CAPRELSA® (vandetanib) for the treatment of aggressive and symptomatic... Leggi tutto
Swissmedic approves Roche drug Perjeta for patients with breast cancer
Basel, 15.08.2012 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Swissmedic (Swiss Agency for Therapeutic Products) has approved Perjeta in Switzerland.Perjeta is indicated in combination... Leggi tutto
Removab
Removab contains the trifunctional antibody, Catumaxomab, which through its targeted mechanism of action destroys cells from EpCAM positive carcinomas. The antibody recognizes a protein on the... Leggi tutto
FDA expands Zytiga’s use for late-stage prostate cancer
The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving... Leggi tutto

Pagine